Skip to main content Skip to navigation

SARS-CoV-2: the functional and dysfunctional immune response

 

Pandemic results in immunological research on SARS-CoV-2

 

In 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease (COVID-19) pandemic, spread rapidly, leading to considerable morbidity and mortality worldwide. High infectivity of the virus, asymptomatic transmission and lack of effective anti-viral drugs and vaccines made management of COVID-19 challenging in the beginning.

 

Continuous efforts to understand the human immune response to SARS-CoV-2 infection and the pathogenesis of this disease may help shed light on the development of therapeutic strategies to better control this ongoing global pandemic.

 

Immune response to SARS-CoV-2

 

In early stage of SARS-CoV-2 infection, a collaborative innate and adaptive immune response is required to clear the virus and prevent disease progression to the severe stage1. During the severe stage of COVID-19, different immune cell types may reach a dysfunctional and exhausted status therefore failing to control virus replication2.

 

The pathobiology of severe cases of COVID-19 is characterised by an increased production of inflammatory cytokines with an influx of immune cells into the lungs, possibly resulting in tissue damage and respiratory failure2.

 

COVID-19: snapshot of the immune response poster

 

We have produced a colourful poster on the immune response to SARS-CoV-2 for you. It is divided into three sections: the functional immune response, the pathobiology of SARS-CoV-2 and the dysfunctional immune response.

 

Through detailed graphics, this poster will give you an in-depth understanding of:

 

  • The viral structure of SARS-CoV-2 and immunopathology in different stages of infection
  • Immune cell types and signaling molecules involved in the response to SARS-CoV-2 infection
  • Differences between the functional and dysfunctional immune responses to SARS-CoV-2 infection

 

 

The information on COVID-19 presented in this poster is relevant as of June 2020 and has not been updated since then.

References

  1. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122-1127. doi:10.1126/science.abm8108
  2. Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. Pulmonology. 2021;27(5):423-437. doi:10.1016/j.pulmoe.2021.03.008

Products are for Research Use Only. Not for use in diagnostic or therapeutic procedures.

BD and the BD Logo are trademarks of Becton, Dickinson and Company. © 2022 BD and its subsidiaries. All rights reserved.